Printed From:

PRALUENT® (alirocumab) Dosing

In patients with clinical ASCVD or HeFH, on top of maximally tolerated statins,

PRALUENT is the only PCSK9i with 2 powerful levels of efficacy to allow you to adjust the dose based on each patient’s LDL-C lowering needs1

The recommended starting dose is 75 mg administered subcutaneously every 2 weeks or alternatively 300 mg every 4 weeks (monthly) for patients who prefer less frequent dosing*

  • The majority of patients achieve sufficient LDL-C reduction with the 75-mg dosage
  • Measure LDL-C levels within 4 to 8 weeks of initiating PRALUENT 75 mg Q2W or just prior to the next scheduled dose for patients receiving PRALUENT 300 mg Q4W
  • If the LDL-C response is inadequate, the dosage may be adjusted to the maximum dosage of 150 mg administered every 2 weeks. For patients adjusting from 300 mg Q4W, start the new dose on the next scheduled dosing date

IMPORTANT SAFETY INFORMATION

  • Local injection site reactions including erythema/redness, itching, swelling, and pain/tenderness were reported more frequently in patients treated with PRALUENT 75 mg and/or 150 mg every 2 weeks (7.2% versus 5.1% for PRALUENT and placebo, respectively). Few patients discontinued treatment because of these reactions (0.2% versus 0.4% for PRALUENT and placebo, respectively), but patients receiving PRALUENT had a greater number of injection site reactions, had more reports of associated symptoms, and had reactions of longer average duration than patients receiving placebo
  • The once-monthly (Q4W) 300 mg dosing regimen had a higher rate of local injection site reactions as compared to PRALUENT 75 mg Q2W or placebo (16.6%, 9.6%, and 7.9%, respectively) in a trial in which all patients received an injection of drug or placebo every 2 weeks to maintain the blind. The discontinuation rate due to injection site reactions was 0.7% in the 300 mg Q4W arm and 0% in the other 2 arms

PRESCRIBE PRALUENT:
LDL-C lowering power with flexible dosing options1

Reference:

  1. PRALUENT® (alirocumab) Prescribing Information. Sanofi and Regeneron Pharmaceuticals.

NEED HELP? CONTACT A REP

Learn more about flexible dosing options from a PRALUENT Field Representative

Contact a rep

THE POWER OF PRALUENT

Get more information on the efficacy of PRALUENT in clinical trials

View efficacy

HOW TO INJECT PRALUENT

See how to administer the PRALUENT Prefilled Pen

Get administration information